搜尋結果

共 2023 個結果
頁數:1...22 23 24 25 26 27 28 29 30 ...102

高盛:藥明發盈喜 連升3日重上80元 留意貼價購18980、高槓桿購19984,貼牛50177

正股表現:藥明生物(02269) 近日觸底反彈,今早繼續造好。早上開市隨即重上80元水平,最高見82.45元, ...全文

港股360輪證攻略2022年02月07日

【異動股】藥明生物升3% 料全年純利增近倍

藥明生物(02269)發盈喜,料全年純利增近倍,股價今早高開3.1%報82元,最新升2%報81.15元,成交逾 ...全文

即時新聞港股直擊2022年02月07日

Submerged by COVID

The wildfire spread of the Omicron variant adds a new element of uncertainty to the global economy. But when it comes to emerging markets, the consensus view is that these countries’ prospects remain ...More

EJ Insight2022-02-04

Fed under pressure to tighten rates more rapidly

When the FOMC meets on 26 January, Chair Jerome Powell said that the U.S. labour market conditions are consistent with maximum employment, a milestone that comes nearly two years after the pandemic fi ...More

EJ Insight2022-01-31

How much has the pandemic cost?

As the COVID-19 pandemic entered its third year, the United States was enjoying a protracted stock-market boom, and China’s global trade surplus had reached record highs. There is reason to believe th ...More

EJ Insight2022-01-28

Minimize the impact of ransomware attack

Dealing with a ransomware attack during the COVID-19 pandemic could be a nightmare scenario. According to a ransomware report, the average ransomware payment in the first half of 2021 Q1 was US$ 0.57 ...More

EJ Insight2022-01-28

COVID-19 mess: We need an exit strategy

We need an exit strategy. Several key propositions unde ...全文

今日信報時事評論EJ InsightBrian Wong2022年01月28日

The necessary rise of Africa's health tech

Africa’s health systems suffer from serious inefficiencies. Countries across the continent struggle with disruptions in medical equipment and drug supply chains, last-mile health-services delivery, me ...More

EJ Insight2022-01-27

The nightmare of being the close contact person

Something is worse than Omicron. It is bad to be infected with Covid-19, but even worse if you are deemed as the close contact person. Hong Kong people are bracing for a not very Happy New Year next w ...More

EJ Insight2022-01-26

能否預測Omicron影響何時結束

兩年多來,2019年冠狀病毒疾病(COVID-19)大流行一直影響着我們的社交、財務和其他日常活動。截至今年1 ...全文

今日信報時事評論蘇家培 朱文英 羅鳳儀2022年01月26日

COVID-19 mess: We need an exit strategy

We need an exit strategy. Several key propositions undergirding this statement – and, indeed, largely informed by recent events. The first, is the hyper-contagiousness of the Omicron (both B.1 and B.2 ...More

EJ Insight2022-01-25

Employment prospects in 2030

According to the results of separate surveys by the Baptist University, human resources organization ECA International, and employment service firm JobsDB HK, the salary of Hong Kong employees is expe ...More

EJ Insight2022-01-24

Domino's調度得宜 疫境中化危為機

新冠疫情下驅使外賣需求大增也許是單次事件,但在家工作卻大機會成為常態(就算是辦公室—家居混合上班模式,也會有外 ...全文

今日信報理財投資上善若水姚穎謙2022年01月22日

從攀緣看Omicron

世間萬事萬物,皆有相遇的可能,道是有緣,緣深緣淺,無處不在。有緣者,相視一笑,已有感應。無緣者,相聚卻如同陌路 ...全文

今日信報副刊文化拾趣人生岑逸飛2022年01月22日

How Facebook became the opium of the masses

In the war on disinformation, the enemy can be hard to determine. Journalists, politicians, governments, and even grandparents have been accused of enabling the spread of online falsehoods. While none ...More

EJ Insight2022-01-21

三葉草生物-B(02197) 其他-業務發展最新情況

三葉草生物-B(02197) 自願公告 - 於《柳葉刀》刊發研究顯示SCB-2019(CpG 1018加鋁佐劑 ...全文

即時新聞港交所通告2022年01月21日

撥開陰霾見青天

新冠疫情大流行至今,世界面對新冠病毒株Omicron的衝擊,各國都爭分奪秒思索應該如何走出經濟發展步伐放慢、人 ...全文

今日信報副刊文化天祐醫言黃天祐醫生2022年01月20日

聯泰控股(00311) 盈利警告 / 內幕消息

聯泰控股(00311) 盈利預告及有關COVID-19疫苗接種率的最新情況(329KB, pdf) ...全文

即時新聞港交所通告2022年01月19日

【輪證贏家】恒指彈高 「人道」對Put

噚日我諗最震驚港人嘅新聞,都莫過於要撲殺2000隻倉鼠及細小動物(包括龍貓同兔仔),2000條生命就咁樣因為幾 ...全文

即時新聞即巿股評2022年01月19日

A pro-family agenda for America starts in California

As of early 2022, the fate of US President Joe Biden’s ambitious plan for delivering an equitable and sustainable economic recovery is uncertain. Failure to pass the $1.75 trillion Build Back Better ( ...More

EJ Insight2022-01-19

頁數:1...22 23 24 25 26 27 28 29 30 ...102

信報簡介 | 服務條款 | 私隱條款 | 免責聲明 | 廣告查詢 | 加入信報 | 聯絡信報

股票及指數資料由財經智珠網有限公司提供。期貨指數資料由天滙財經有限公司提供。外滙及黃金報價由路透社提供。

本網站的內容概不構成任何投資意見,本網站內容亦並非就任何個別投資者的特定投資目標、財務狀況及個別需要而編製。投資者不應只按本網站內容進行投資。在作出任何投資決定前,投資者應考慮產品的特點、其本身的投資目標、可承受的風險程度及其他因素,並適當地尋求獨立的財務及專業意見。本網站及其資訊供應商竭力提供準確而可靠的資料,但並不保證資料絕對無誤,資料如有錯漏而令閣下蒙受損失,本公司概不負責。